- Home
- LPLA vs INSM Comparison
LPLA vs INSM Comparison
Compare LPLA & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPLA
- INSM
- Stock Information
- Founded
- LPLA 1989
- INSM 1988
- Country
- LPLA United States
- INSM United States
- Employees
- LPLA N/A
- INSM N/A
- Industry
- LPLA Investment Bankers/Brokers/Service
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- LPLA Finance
- INSM Health Care
- Exchange
- LPLA Nasdaq
- INSM Nasdaq
- Market Cap
- LPLA 30.4B
- INSM 26.0B
- IPO Year
- LPLA 2010
- INSM 2000
- Fundamental
- Price
- LPLA $340.52
- INSM $146.68
- Analyst Decision
- LPLA Buy
- INSM Strong Buy
- Analyst Count
- LPLA 13
- INSM 19
- Target Price
- LPLA $399.77
- INSM $146.81
- AVG Volume (30 Days)
- LPLA 790.6K
- INSM 2.9M
- Earning Date
- LPLA 10-29-2025
- INSM 10-30-2025
- Dividend Yield
- LPLA 0.35%
- INSM N/A
- EPS Growth
- LPLA 14.09
- INSM N/A
- EPS
- LPLA 14.60
- INSM N/A
- Revenue
- LPLA $13,758,121,000.00
- INSM $398,105,000.00
- Revenue This Year
- LPLA $33.13
- INSM $32.47
- Revenue Next Year
- LPLA $17.04
- INSM $126.03
- P/E Ratio
- LPLA $23.35
- INSM N/A
- Revenue Growth
- LPLA 28.54
- INSM 21.15
- 52 Week Low
- LPLA $204.41
- INSM $60.40
- 52 Week High
- LPLA $403.58
- INSM $146.91
- Technical
- Relative Strength Index (RSI)
- LPLA 36.53
- INSM 80.87
- Support Level
- LPLA $328.40
- INSM $140.33
- Resistance Level
- LPLA $364.58
- INSM $146.84
- Average True Range (ATR)
- LPLA 10.15
- INSM 3.63
- MACD
- LPLA -1.85
- INSM 0.68
- Stochastic Oscillator
- LPLA 28.11
- INSM 98.90
About LPLA LPL Financial Holdings Inc.
LPL Financial Holdings is an independent broker/dealer that provides a platform of proprietary technology, brokerage, and investment advisory services to financial advisors and institutions. As of the end of 2024, the company had over 29,000 advisors on its platform managing $1.7 trillion of client assets. The company doesn't have material operations outside the United States.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.